6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A new probe drug cocktail containing substrates of important drug transporters was tested for mutual interactions in a clinical trial. The cocktail consisted of (predominant transporter; primary phenotyping metric): 10 mg adefovir-dipivoxil (OAT1; renal clearance (CLR )), 100 mg sitagliptin (OAT3; CLR ), 500 mg metformin (several renal transporters; CLR ), 2 mg pitavastatin (OATP1B1; clearance/F), and 0.5 mg digoxin (intestinal P-gp, renal P-gp, and OATP4C1; peak plasma concentration (Cmax ) and CLR ). Using a randomized six-period, open change-over design, single oral doses were administrated either concomitantly or separately to 24 healthy male and female volunteers. Phenotyping metrics were evaluated by noncompartmental analysis and compared between periods by the standard average bioequivalence approach (boundaries for ratios 0.80-1.25). Primary metrics supported the absence of relevant interactions, whereas secondary metrics suggested that mainly adefovir was a victim of minor drug-drug interactions (DDIs). All drugs were well tolerated. This cocktail may be another useful tool to assess transporter-based DDIs in vivo.

          Related collections

          Author and article information

          Journal
          Clin Pharmacol Ther
          Clinical pharmacology and therapeutics
          Wiley
          1532-6535
          0009-9236
          December 2019
          : 106
          : 6
          Affiliations
          [1 ] University of Cologne, Faculty of Medicine and University Hospital Cologne, Center for Pharmacology, Department I of Pharmacology, Cologne, Germany.
          [2 ] Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany.
          [3 ] Dr. Margarete-Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
          [4 ] University of Tuebingen, Tuebingen, Germany.
          [5 ] Hospital Pharmacy, University Hospital Cologne, Cologne, Germany.
          [6 ] Department of Clinical Pharmacy, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
          [7 ] Department of Clinical Pharmacology, University Hospital Tuebingen, Tuebingen, Germany.
          [8 ] Department of Pharmacy and Biochemistry, University of Tuebingen, Tuebingen, Germany.
          [9 ] Institute of Pharmacology, Faculty of Medicine, University Duisburg-Essen, Essen, Germany.
          Article
          10.1002/cpt.1564
          31247117
          717c629b-6239-427b-b391-089b7234d166
          © 2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics.
          History

          Comments

          Comment on this article